Autopsy report · NCT03502694
Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human Metapneumovirus
Cause of deathFunding or business
“sponsor decision”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 2
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Industry
- Conditions
- Metapneumovirus
- Interventions
- Lumicitabine; Placebo
- Participants
- 0
- Sites
- 112
- Countries
- Argentina, Australia, Brazil, Bulgaria, France, Japan, Malaysia, Netherlands, Poland, Russia, South Korea, Spain and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.